| Bioactivity | Sacituzumab tirumotecan (SKB264/MK-2870) is a TROP2 ADC. Sacituzumab tirumotecan can be used for the research of triple-negative breast cancer (TNBC)[1]. |
| CAS | 2768350-77-0 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Xu B, et, al. Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study. Special Clinical Science Symposia. May 29, 2024. |